Catalyst Pharmaceuticals Insider Trade Highlights Stock Movement

Author: Logan Wright Updated: 08-29-2025 11:47 AM

Recent Insider Sale at Catalyst Pharmaceuticals

David S Tierney, the Director at Catalyst Pharmaceuticals (NASDAQ: CPRX), recently executed a notable sale of stocks amounting to $525,200. This sale involved the transfer of 26,000 shares, as documented in an SEC Form 4 filing.

Catalyst Pharmaceuticals: Company Overview

Catalyst Pharmaceuticals Inc is dedicated to developing and marketing therapeutics for individuals suffering from rare, chronic neuromuscular and neurological diseases. The company boasts a refined portfolio that includes three significant drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Stock Performance Insights

As of the current trading session, shares of Catalyst Pharmaceuticals are priced at $20.49, up by 0.54%. This performance indicates a steady growth trajectory, showcasing the company's resilience in a fluctuating market.

Analyzing the Economic Impact

The economic data reflects a promising growth pattern for Catalyst Pharmaceuticals. Recent figures indicate a remarkable revenue growth rate of 19.44% for the last quarter, which, while admirable, falls short of the average growth rates seen across industry peers in the Health Care sector.

Profitability and Financial Health

Gross Margin: Demonstrating excellent cost management, the company has achieved a gross margin of 85.94%.
Earnings per Share (EPS): Catalyst Pharmaceuticals has posted an EPS of 0.43, outperforming many competitors within the industry.

Moreover, the company's debt-to-equity ratio stands impressively low at 0.0, signifying robust financial health.

Valuation Metrics Analysis

Price to Earnings (P/E) Ratio: Currently at 12.35, this ratio indicates that the stock may be undervalued, offering an attractive investment opportunity.
Price to Sales (P/S) Ratio: The P/S ratio is reported at 4.62, again suggesting a possibly discounted valuation against sales performance.
EV/EBITDA Ratio: With an EV/EBITDA ratio of 6.56, Catalyst Pharmaceuticals ranks below market averages, marking potential undervaluation.

The Role of Insider Transactions

Insider transactions, such as this recent stock sale, often draw investor attention. While insider sells can indicate various motivations, they are not necessarily indicative of negative expectations for the company’s future. Understanding the legal framework around these transactions is essential, as insiders must report any trades within a set timeframe according to securities regulations.

Understanding Stock Transactions and Their Codes

Stock transactions are categorized by codes in SEC filings. The letter P refers to a purchase, whereas S indicates a sale. This system ensures transparency and helps investors analyze insider activity in the markets.

Frequently Asked Questions

What recent event has occurred with Catalyst Pharmaceuticals?

The Director, David S Tierney, sold 26,000 shares of the company totaling $525,200.

What is the current stock price of Catalyst Pharmaceuticals?

As of the latest update, the stock is trading at $20.49.

What are the main products offered by Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals offers FIRDAPSE, FYCOMPA, and AGAMREE.

How does Catalyst Pharmaceuticals' financial health appear?

The company exhibits a strong financial position, with a low debt-to-equity ratio and healthy gross margins.

What are insider sales indicative of?

While often scrutinized, insider sales do not inherently signal negative company performance, as they can result from various personal financial decisions.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.